These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10586326)

  • 1. Atorvastatin and low-density lipoprotein subfractions profile in mixed hyperlipidaemia: a contributory effect of reduced hepatic lipase activity?
    Heller F; Descamps O; Hondekijn JC; Desager JP
    Ann Clin Biochem; 1999 Nov; 36 ( Pt 6)():788-9. PubMed ID: 10586326
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
    Xu RX; Guo YL; Li XL; Li S; Li JJ
    Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):475-81. PubMed ID: 24739131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
    McKenney JM; McCormick LS; Schaefer EJ; Black DM; Watkins ML
    Am J Cardiol; 2001 Aug; 88(3):270-4. PubMed ID: 11472706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin in the management of an index patient with complete hepatic lipase deficiency.
    Hegele RA; Little JA; Connelly PW
    Atherosclerosis; 1999 Mar; 143(1):219-22. PubMed ID: 10208500
    [No Abstract]   [Full Text] [Related]  

  • 5. Elevated lipoprotein(a) with statin therapy.
    Spielberg T
    Am J Cardiol; 2000 May; 85(9):1162. PubMed ID: 10896622
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
    van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
    J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
    Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of atorvastatin on total lipid profiles assessed by analytical capillary isotachophoresis.
    Zhang B; Noda K; Saku K
    Cardiology; 2003; 99(4):211-3. PubMed ID: 12845248
    [No Abstract]   [Full Text] [Related]  

  • 11. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials.
    Takagi H; Umemoto T
    Int J Cardiol; 2012 Jan; 154(2):183-6. PubMed ID: 21996415
    [No Abstract]   [Full Text] [Related]  

  • 12. [AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].
    Z Kardiol; 1999 Mar; 88(3 Suppl):1-4. PubMed ID: 10330699
    [No Abstract]   [Full Text] [Related]  

  • 13. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemorrhagic stroke in the SPARCL study.
    Mascitelli L; Pezzetta F; Goldstein MR
    Stroke; 2008 Nov; 39(11):e180; author reply e181. PubMed ID: 18832743
    [No Abstract]   [Full Text] [Related]  

  • 15. Atorvastatin for protease inhibitor-related hyperlipidaemia.
    Murillas J; Martín T; Ramos A; Portero JL
    AIDS; 1999 Jul; 13(11):1424-5. PubMed ID: 10449305
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.
    Yasuda G; Ando D; Hirawa N; Umemura S
    Ren Fail; 2010 Jul; 32(6):680-6. PubMed ID: 20540635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin in dyslipidaemia of the nephrotic syndrome.
    Valdivielso P; Moliz M; Valera A; Corrales MA; Sanchez-Chaparro MA; Gonzalez-Santos P
    Nephrology (Carlton); 2003 Apr; 8(2):61-4. PubMed ID: 15012735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):85-6. PubMed ID: 15727720
    [No Abstract]   [Full Text] [Related]  

  • 19. Atorvastatin: in the management of hyperlipidaemia.
    Ray SK; Rege NN
    J Postgrad Med; 2000; 46(3):242-3. PubMed ID: 11298482
    [No Abstract]   [Full Text] [Related]  

  • 20. A low-density lipoprotein-dependent effect of atorvastatin upon the systolic blood pressure reduction: meta-regression analyses of randomized trials.
    Takagi H; Umemoto T;
    Int J Cardiol; 2013 Dec; 170(1):e14-6. PubMed ID: 24169537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.